SG11201501715QA - Stable aqueous formulations of adalimumab - Google Patents

Stable aqueous formulations of adalimumab

Info

Publication number
SG11201501715QA
SG11201501715QA SG11201501715QA SG11201501715QA SG11201501715QA SG 11201501715Q A SG11201501715Q A SG 11201501715QA SG 11201501715Q A SG11201501715Q A SG 11201501715QA SG 11201501715Q A SG11201501715Q A SG 11201501715QA SG 11201501715Q A SG11201501715Q A SG 11201501715QA
Authority
SG
Singapore
Prior art keywords
adalimumab
stable aqueous
aqueous formulations
formulations
stable
Prior art date
Application number
SG11201501715QA
Other languages
English (en)
Inventor
Mark Manning
Robert W Payne
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201501715Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of SG11201501715QA publication Critical patent/SG11201501715QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
SG11201501715QA 2012-09-07 2013-09-06 Stable aqueous formulations of adalimumab SG11201501715QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261698138P 2012-09-07 2012-09-07
US201361769581P 2013-02-26 2013-02-26
US201361770421P 2013-02-28 2013-02-28
PCT/US2013/058618 WO2014039903A2 (en) 2012-09-07 2013-09-06 Stable aqueous formulations of adalimumab

Publications (1)

Publication Number Publication Date
SG11201501715QA true SG11201501715QA (en) 2015-05-28

Family

ID=50237778

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201705668XA SG10201705668XA (en) 2012-09-07 2013-09-06 Stable aqueous formulations of adalimumab
SG11201501715QA SG11201501715QA (en) 2012-09-07 2013-09-06 Stable aqueous formulations of adalimumab

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201705668XA SG10201705668XA (en) 2012-09-07 2013-09-06 Stable aqueous formulations of adalimumab

Country Status (31)

Country Link
US (39) US20140186361A1 (de)
EP (2) EP2892550B1 (de)
JP (3) JP6463268B2 (de)
KR (3) KR102362829B1 (de)
CN (1) CN104768576A (de)
AR (1) AR092470A1 (de)
AU (3) AU2013312300A1 (de)
BR (1) BR112015004984A2 (de)
CA (2) CA3153799A1 (de)
CL (1) CL2015000574A1 (de)
CY (1) CY1123407T1 (de)
DK (1) DK2892550T3 (de)
DO (1) DOP2015000051A (de)
EA (2) EA201791717A1 (de)
EC (1) ECSP15013227A (de)
ES (1) ES2784861T3 (de)
HK (1) HK1210601A1 (de)
HR (1) HRP20200434T1 (de)
HU (1) HUE049282T2 (de)
IL (2) IL237583B (de)
LT (1) LT2892550T (de)
MX (1) MX2015003007A (de)
PE (2) PE20191815A1 (de)
PL (1) PL2892550T3 (de)
PT (1) PT2892550T (de)
RS (1) RS60226B1 (de)
SG (2) SG10201705668XA (de)
SI (1) SI2892550T1 (de)
TW (2) TW202042841A (de)
UY (1) UY35351A (de)
WO (1) WO2014039903A2 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP3912639A1 (de) 2012-03-07 2021-11-24 Cadila Healthcare Limited Pharmazeutische formulierungen von tnf-alpha-antikörpern
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EA201791717A1 (ru) 2012-09-07 2018-03-30 Кохерус Байосайенсис, Инк. Стабильные водные составы адалимумаба
CN105051064A (zh) * 2013-01-24 2015-11-11 葛兰素史克知识产权开发有限公司 抗TNF-α抗原结合蛋白
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057910A1 (en) 2013-10-16 2015-04-23 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10688187B2 (en) * 2014-04-02 2020-06-23 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
EP2946767B1 (de) 2014-05-23 2016-10-05 Ares Trading S.A. Flüssige pharmazeutische Zusammensetzung
ES2572919T3 (es) * 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
HUE029849T2 (en) * 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
US20170189528A1 (en) * 2014-06-10 2017-07-06 Meiji Seika Pharma Co., Ltd. Stable aqueous adalimumab formulation
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
AR103544A1 (es) * 2015-01-28 2017-05-17 Mabxience S A FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a
EP3053572A1 (de) * 2015-02-06 2016-08-10 Ares Trading S.A. Flüssige pharmazeutische Zusammensetzung
KR20170117166A (ko) * 2015-02-13 2017-10-20 사노피 단클론 항체를 위한 안정한 액체 제형
WO2016162819A1 (en) 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
US11583584B1 (en) * 2015-10-28 2023-02-21 Coherus Biosciences, Inc. Stable protein compositions and methods of their use
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US20190284282A1 (en) * 2016-01-12 2019-09-19 Dr. Reddy's Laboratories Limited Stable pharmaceutical composition
US11285210B2 (en) 2016-02-03 2022-03-29 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
AU2017223687A1 (en) * 2016-02-23 2018-08-09 Sesen Bio, Inc. IL-6 antagonist formulations and uses thereof
WO2017180594A1 (en) * 2016-04-13 2017-10-19 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
US20180043020A1 (en) * 2016-04-20 2018-02-15 Coherus Biosciences, Inc. Method of reducing immunogenicity of drug products
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
SG11201811320YA (en) 2016-06-30 2019-01-30 Celltrion Inc Stable liquid pharmaceutical preparation
KR20180046888A (ko) * 2016-10-28 2018-05-09 (주)셀트리온 안정한 약제학적 제제
EP3558363A1 (de) * 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf-alpha-antikörperformulierungen
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (de) 2017-03-06 2018-09-12 Ares Trading S.A. Flüssige pharmazeutische zusammensetzung
EP3372242A1 (de) * 2017-03-06 2018-09-12 Ares Trading S.A. Flüssige pharmazeutische zusammensetzung
KR20180106974A (ko) * 2017-03-16 2018-10-01 주식회사 엘지화학 항-tnf 알파 항체의 액상 제제
WO2018184692A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
WO2018184693A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
CA3076423A1 (en) * 2017-09-20 2019-03-28 Alvotech Hf Pharmaceutical formulations for adalimumab
AU2020207124A1 (en) * 2019-01-11 2021-07-29 Samsung Bioepis Co., Ltd. Pharmaceutical composition comprising antibody, device comprising same, and use thereof
CN113474360A (zh) * 2019-02-18 2021-10-01 伊莱利利公司 治疗性抗体制剂
WO2021038532A1 (en) * 2019-08-30 2021-03-04 Kashiv Biosciences, Llc Novel formulation of highly concentrated pharmacologically active antibody
EP4119161A4 (de) * 2020-03-13 2024-05-15 Samsung Bioepis Co., Ltd. Flüssige pharmazeutische zusammensetzung mit verbesserter stabilität
US20230158143A1 (en) * 2020-05-21 2023-05-25 Shilpa Medicare Ltd Pharmaceutical compositions comprising adalimumab
WO2022187834A1 (en) * 2021-03-03 2022-09-09 Allakos Inc. Anti-siglec-8 antibody formulations
WO2023037384A1 (en) * 2021-09-07 2023-03-16 Dr. Reddy's Laboratories Limited Formulations of immune check point inhibitors or like
AU2022348349A1 (en) * 2021-09-16 2024-05-02 Aprogen Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TNFα ANTIBODY
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂
WO2023183898A1 (en) * 2022-03-24 2023-09-28 Arch Oncology, Inc. Formulations for anti-cd47 antibodies

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
KR100365171B1 (ko) 1994-08-08 2003-02-19 드바이오팜 에스.아. 약학적으로안정한옥살리플라티늄제제
WO1996004925A1 (en) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6171576B1 (en) 1995-11-03 2001-01-09 Organix Inc. Dopamine transporter imaging agent
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
NZ512006A (en) 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
JP2000516594A (ja) 1996-07-26 2000-12-12 スミスクライン・ビーチャム・コーポレイション 免疫細胞介在全身性疾患の改良された治療法
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
ES2190087T3 (es) * 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6171686B1 (en) 1997-10-03 2001-01-09 Marine Environmental Solutions, L.L.C. Synthetic aquatic structure
ATE220558T1 (de) 1997-11-22 2002-08-15 Roche Diagnostics Gmbh Verbessertes verfahren zur stabilisierung von proteinen
AU2444899A (en) 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
ES2527915T3 (es) 1998-06-09 2015-02-02 Csl Behring Ag Producto de inmunoglobulina G (IgG) líquido
CN101066997B (zh) 1999-03-25 2013-03-27 艾博特股份有限两合公司 结合人il-12的人抗体及其生产方法
IL145816A0 (en) 1999-04-09 2002-07-25 Ortho Mcneil Pharm Inc Pharmaceutical compositions of erythropoietin
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
US20030124119A1 (en) * 1999-12-28 2003-07-03 Tadao Yamazaki Stable antibody compositions and injection preparations
EP1336410A4 (de) 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd Protein-injektionszubereitungen
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
EP1314437B1 (de) * 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Antikörper enthaltende stabilisierte präparate
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TR201809008T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
JP5290489B2 (ja) * 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
ATE402716T1 (de) 2002-02-27 2008-08-15 Immunex Corp Stabilisierte tnfr-fc formulierung mit arginin
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
CN1668332A (zh) 2002-07-09 2005-09-14 桑多斯股份公司 包含苯酚的含高浓度人生长激素的液体制剂
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
DE60326012D1 (de) 2002-11-01 2009-03-12 Bayer Healthcare Llc Verfahren zur Konzentration von Proteinen
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
JPWO2005063291A1 (ja) * 2003-12-25 2007-07-19 麒麟麦酒株式会社 抗体を含有する安定な水性医薬製剤
WO2006022599A1 (en) 2004-08-27 2006-03-02 Marian Metke Production method for exfoliated graphite, equipment for its production, exfoliated graphite and means of its use
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
ES2436616T5 (es) 2005-12-20 2022-05-27 Bristol Myers Squibb Co Formulaciones proteicas estables
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
ES2925992T3 (es) 2006-10-20 2022-10-20 Amgen Inc Formulaciones estables de polipéptidos
US20110130544A1 (en) * 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
WO2008135380A1 (en) 2007-05-02 2008-11-13 F. Hoffmann-La Roche Ag Method for stabilizing a protein
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
US20090151807A1 (en) 2007-08-07 2009-06-18 Davis Chanda Janese Container Insert for Zero Headspace
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CN101969971A (zh) 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
WO2009073805A2 (en) 2007-12-04 2009-06-11 Verdezyne, Inc. Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
NZ601913A (en) * 2008-01-15 2014-02-28 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
MX2011004200A (es) * 2008-10-20 2011-05-24 Abbott Lab Aislamento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a.
BRPI0921320A2 (pt) 2008-11-28 2018-05-22 Abbott Laboratories composições de anticorpo estáveis e métodos para estabilizar os mesmos
JP2012511531A (ja) 2008-12-09 2012-05-24 エフ．ホフマン−ラ ロシュ アーゲー 賦形剤不含抗体溶液を得るための方法
US20100278822A1 (en) 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
KR101333276B1 (ko) 2009-11-20 2013-11-27 센트로 데 인무노로지아 몰레큘라 항체의 제제
JP2013515754A (ja) * 2009-12-29 2013-05-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規な抗体製剤
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
EP2568960B1 (de) 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Flüssige formulierung aus polypeptiden mit einer fc-domäne eines immunglobulins
FR2961107B1 (fr) 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
CH703405B1 (de) 2010-07-05 2014-05-15 Melexis Tessenderlo Nv Magnetischer Winkelsensor.
ES2665954T3 (es) * 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
CN103282042B (zh) * 2010-09-17 2014-12-10 巴克斯特国际公司 通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白
CN105854016A (zh) 2010-11-11 2016-08-17 艾伯维生物技术有限公司 改进的高浓度抗TNFα抗体液体制剂
EP2471554A1 (de) 2010-12-28 2012-07-04 Hexal AG Pharmazeutische Formulierung mit biopharmazeutischem Arzneimittel
US9453067B2 (en) 2011-04-20 2016-09-27 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
SG194445A1 (en) 2011-05-19 2013-12-30 Novartis Ag Method for treating adenoid cystic carcinoma
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US10995130B2 (en) 2011-07-01 2021-05-04 Biogen Ma Inc. Arginine-free TNFR:Fc-fusion polypeptide compositions and methods of use
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
EP2771033A4 (de) 2011-10-28 2016-02-17 Integritybio Inc Proteinformulierungen mit aminosäuren
WO2013096835A1 (en) 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
EP3912639A1 (de) 2012-03-07 2021-11-24 Cadila Healthcare Limited Pharmazeutische formulierungen von tnf-alpha-antikörpern
EP2863951A1 (de) 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmazeutische formulierung für einen therapeutischen antikörper
US20150102042A1 (en) 2012-07-10 2015-04-16 Gary Matsch Air Purging Lid
EA201791717A1 (ru) 2012-09-07 2018-03-30 Кохерус Байосайенсис, Инк. Стабильные водные составы адалимумаба
US9844594B2 (en) 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
CN102988984B (zh) 2012-12-21 2015-05-20 嘉和生物药业有限公司 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂
WO2014186230A1 (en) 2013-05-13 2014-11-20 Endochoice, Inc. An endoscope tip position visual indicator and heat management system
US9681695B2 (en) 2013-07-31 2017-06-20 Sport Maska Inc. Helmet with chin cup

Also Published As

Publication number Publication date
EA201791717A1 (ru) 2018-03-30
KR102238677B1 (ko) 2021-04-12
CA2884182A1 (en) 2014-03-13
US20180028653A1 (en) 2018-02-01
US9707293B2 (en) 2017-07-18
US20180028656A1 (en) 2018-02-01
LT2892550T (lt) 2020-04-10
HUE049282T2 (hu) 2020-09-28
US10799585B2 (en) 2020-10-13
US20150190513A1 (en) 2015-07-09
US20160039926A1 (en) 2016-02-11
US9808525B2 (en) 2017-11-07
HRP20200434T1 (hr) 2020-07-24
CY1123407T1 (el) 2021-12-31
EA029215B1 (ru) 2018-02-28
HK1210601A1 (en) 2016-04-29
TWI698253B (zh) 2020-07-11
US10786566B2 (en) 2020-09-29
US10286071B2 (en) 2019-05-14
US10159733B2 (en) 2018-12-25
DK2892550T3 (da) 2020-03-30
US20160304601A1 (en) 2016-10-20
CA3153799A1 (en) 2014-03-13
KR102362829B1 (ko) 2022-02-15
US20180021433A1 (en) 2018-01-25
US10722579B2 (en) 2020-07-28
US20160256546A1 (en) 2016-09-08
IL277652A (en) 2020-11-30
US20160303234A1 (en) 2016-10-20
US9724414B2 (en) 2017-08-08
DOP2015000051A (es) 2015-05-31
US20160303235A1 (en) 2016-10-20
US10780163B2 (en) 2020-09-22
US10286072B2 (en) 2019-05-14
EP3701968A1 (de) 2020-09-02
US9782479B2 (en) 2017-10-10
US9682145B2 (en) 2017-06-20
SG10201705668XA (en) 2017-08-30
US10207000B2 (en) 2019-02-19
US20170072054A1 (en) 2017-03-16
JP6463268B2 (ja) 2019-01-30
US20160304599A1 (en) 2016-10-20
AU2020202912A1 (en) 2020-05-21
US20160256547A1 (en) 2016-09-08
US10716854B2 (en) 2020-07-21
AU2013312300A1 (en) 2015-04-16
US20170312361A1 (en) 2017-11-02
US9737600B2 (en) 2017-08-22
US20180043018A1 (en) 2018-02-15
AU2018208699A1 (en) 2018-08-16
US20150190512A1 (en) 2015-07-09
BR112015004984A2 (pt) 2017-07-04
EP2892550A4 (de) 2016-04-13
US20180028654A1 (en) 2018-02-01
ES2784861T3 (es) 2020-10-01
US20180055929A1 (en) 2018-03-01
US20180311352A1 (en) 2018-11-01
US20150182626A1 (en) 2015-07-02
US10195275B2 (en) 2019-02-05
KR20210040470A (ko) 2021-04-13
CL2015000574A1 (es) 2015-10-23
PE20191815A1 (es) 2019-12-27
SI2892550T1 (sl) 2020-11-30
US9731009B2 (en) 2017-08-15
US9724415B2 (en) 2017-08-08
EA201590518A1 (ru) 2016-05-31
US9340612B2 (en) 2016-05-17
WO2014039903A2 (en) 2014-03-13
US20160303233A1 (en) 2016-10-20
MX2015003007A (es) 2015-06-05
US20180311349A1 (en) 2018-11-01
IL277652B (en) 2022-09-01
IL237583B (en) 2020-10-29
US20180140701A1 (en) 2018-05-24
CN104768576A (zh) 2015-07-08
US9340611B2 (en) 2016-05-17
US20150191539A1 (en) 2015-07-09
JP2019069993A (ja) 2019-05-09
PE20150964A1 (es) 2015-07-25
JP2021020930A (ja) 2021-02-18
US20190070293A1 (en) 2019-03-07
US9770507B2 (en) 2017-09-26
CA2884182C (en) 2022-06-14
ECSP15013227A (es) 2016-01-29
US9782480B2 (en) 2017-10-10
IL237583A0 (en) 2015-04-30
TW202042841A (zh) 2020-12-01
US10772959B2 (en) 2020-09-15
US20190060455A1 (en) 2019-02-28
US9789185B2 (en) 2017-10-17
US10716852B2 (en) 2020-07-21
US20160263226A1 (en) 2016-09-15
EP2892550A2 (de) 2015-07-15
AR092470A1 (es) 2015-04-22
TW201424749A (zh) 2014-07-01
US20140186361A1 (en) 2014-07-03
US9861695B2 (en) 2018-01-09
US20160031982A1 (en) 2016-02-04
US20180043019A1 (en) 2018-02-15
US20180055930A1 (en) 2018-03-01
PL2892550T3 (pl) 2020-07-27
WO2014039903A3 (en) 2014-06-26
IL277652B2 (en) 2023-04-01
US10159732B2 (en) 2018-12-25
JP6783845B2 (ja) 2020-11-11
US10772960B2 (en) 2020-09-15
JP2015527402A (ja) 2015-09-17
US10716853B2 (en) 2020-07-21
US20180311350A1 (en) 2018-11-01
US20190070292A1 (en) 2019-03-07
US20180311351A1 (en) 2018-11-01
US20180028655A1 (en) 2018-02-01
US10155039B2 (en) 2018-12-18
US20190070294A1 (en) 2019-03-07
US9346880B2 (en) 2016-05-24
US9731008B2 (en) 2017-08-15
US20180028657A1 (en) 2018-02-01
US20150191538A1 (en) 2015-07-09
KR20150047140A (ko) 2015-05-04
US9382317B2 (en) 2016-07-05
US20160304600A1 (en) 2016-10-20
UY35351A (es) 2014-08-29
KR20220025196A (ko) 2022-03-03
PT2892550T (pt) 2020-03-27
US9757454B2 (en) 2017-09-12
US10688183B2 (en) 2020-06-23
EP2892550B1 (de) 2019-12-18
RS60226B1 (sr) 2020-06-30
US20160256545A1 (en) 2016-09-08

Similar Documents

Publication Publication Date Title
IL277652A (en) Stable aqueous formulations of adlimumab
HK1213174A1 (zh) 穩定的含水依那西普製劑
HK1212701A1 (zh) 恩雜魯胺製劑
PL3336097T3 (pl) Wytwarzanie niekrystalicznej postaci kwasu obetycholowego
HK1210914A1 (en) Formulations of clomazone
ZA201406082B (en) Use of ccr3-inhibitors
PL2934134T3 (pl) Zastosowania inhalacji kwasem acetylosalicylowym
IL236312A0 (en) Preparation of 18f-flucyclobin
PT2908835T (pt) Formulações estáveis
SG11201503051QA (en) Formulations of pyrimidinedione derivative compounds
EP2892529A4 (de) Verwendungen von (-)-perhexilin
EP2782902A4 (de) Derivate aus phenoxyisobuttersäure
IL233879A0 (en) Dry powdered dnase i preparations
HUE036665T2 (hu) Dihidro-pirido-oxazin származék szilárd formái